Contract drug developer Recipharm has inked a deal with Swedish biotech Follicum to help get the company's top prospect into clinical trials, handling formulation and production.
Two years after Celgene dangled a selection of $225 million milestone prizes in front of bluebird bio in exchange for collaborating on a range of CAR-T cancer drug programs, the Big Biotech has narrowed its sights to a single target and chipped in a $25 million payment to move their lead candidate into the clinic soon.
Contract drugmaker AMRI is shifting some of its focus to early-stage R&D, partnering up with a neighboring biotech to expand its capabilities in drug discovery.
New startup LaunchPad Medical has in-licensed a bone adhesive candidate from Stryker. The company is headed by a former R&D manager at Stryker, Brian Hess, who the company named Co-Innovator of the Year in 2010 for his work on this bone adhesive, Tetranite.
South Korea's SK Biopharmaceuticals announced Phase III clinical trials of a medication for sleep disorders that will be led abroad by partner U.S.-based Jazz Pharmaceuticals, the Korea Herald said.
Baxter, soon to spin out its drug business, is seeding a biotech upstart with the help of the Mayo Clinic, divvying up the labors of R&D in hopes of spurring the discovery of new therapies.
Novocure released clinical trial data at the American Society of Clinical Oncology meeting showing that its cancer-fighting Optune device improves survival in newly diagnosed brain cancer patients, and hopes the new information will lead to an expanded indication from the FDA, which currently permits use of the only wearable anticancer device in recurrent glioblastoma patients.
AstraZeneca Pharma India has signed up Dr. Reddy's Laboratories to distribute its diabetes medicines Riax and Riax-M in India as domestic and foreign companies look for advantages in a crucial and sharply competitive market where generic activity is on the rise.
AstraZeneca believes the brightest future for its top oncology prospect will come through collaboration, recruiting Eli Lilly to its growing ranks of partners with eyes on kicking off a combination cancer trial.
The Japan Agency for Medical Research and Development, created less than two months ago in the model of the U.S. NIH, is now ready to receive up to 200,000 substance samples from more than 10 drugmakers. In exchange for providing the substances free of charge, AMED said it would work with universities and other researchers to test a substance's use in treating various diseases and ailments, such as cancer and infection.